Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

 Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

Pfizer Signs an Agreement with SpringWorks to Evaluate Nirogacestat + PF‐06863135 for R/R Multiple Myeloma

Shots:  

  • Pfizer to sponsor & conduct P-Ib/II study evaluating the safety, tolerability, and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights.  The companies will form a joint development committee to manage clinical study which is anticipated to commence in H1’21
  • The focus of the collaboration is to evaluate SpringWorks’ Nirogacestat + Pfizer’s PF‐06863135, in patients with r/r MM. Additionally, SpringWorks is currently conducting a global P-III DeFi trial to evaluate nirogacestat in adults with progressing desmoid tumors
  • Nirogacestat is investigational, oral, selective, small-molecule GSI in P-III while PF‐06863135 is anti-BCMA CD3 bispecific Ab (SC), being investigated in P-I study to treat r/r MM

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Solar Winds MSP

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post